{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:56Z","timestamp":1790796236744,"version":"4.1.0"},"reference-count":10,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine High Impact Case Reports"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Acute interstitial nephritis (AIN) is a relatively common cause of acute kidney injury with etiologies that include drug therapy, infections, and systemic diseases. Of these etiologies, drug therapy accounts for ~70% of AIN cases. Although any drug can cause AIN, there are no reported cases of AIN caused by omalizumab, a humanized monoclonal antibody that binds to and inhibits circulating immunoglobulin E. In this article, we share the first reported case of AIN following administration of omalizumab for the treatment of moderate to severe persistent asthma.<\/jats:p>","DOI":"10.1177\/2324709620946890","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:45:44Z","timestamp":1596271544000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute Interstitial Nephritis: A Rare and Unusual Side Effect of Omalizumab"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7081-7222","authenticated-orcid":false,"given":"Rocky","family":"Yang","sequence":"first","affiliation":[{"name":"Kern Medical Center\u2014UCLA, Bakersfield, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-910X","authenticated-orcid":false,"given":"Leila","family":"Moosavi","sequence":"additional","affiliation":[{"name":"American University of the Caribbean, Pembroke Pines, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabitha","family":"Eppanapally","sequence":"additional","affiliation":[{"name":"American University of the Caribbean, Pembroke Pines, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayham","family":"Aboeed","sequence":"additional","affiliation":[{"name":"American University of the Caribbean, Pembroke Pines, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Munoz","sequence":"additional","affiliation":[{"name":"American University of the Caribbean, Pembroke Pines, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"bibr1-2324709620946890","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.160490"},{"key":"bibr2-2324709620946890","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s49409"},{"key":"bibr3-2324709620946890","unstructured":"US Food and Drug Administration. Omalizumab (marketed as Xolair) information. Accessed July 17, 2020. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/omalizumab-marketed-xolair-information"},{"key":"bibr4-2324709620946890","unstructured":"Xolair [package insert]. Francisco, CA: Genentech, Inc; 2019. Accessed July 17, 2020. https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf"},{"key":"bibr5-2324709620946890","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. Accessed July 17, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-approves-label-changes-asthma-drug-xolair-omalizumab-including"},{"key":"bibr6-2324709620946890","unstructured":"Mayo Clinic. Xolair (omalizumab) for treatment of drug-induced acute tubulointerstitial nephritis (AIN). Accessed July 17, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01893658"},{"key":"bibr7-2324709620946890","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07630717"},{"key":"bibr8-2324709620946890","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018050488"},{"key":"bibr9-2324709620946890","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02340219"},{"key":"bibr10-2324709620946890","first-page":"3","volume":"9","author":"Krishnan N","year":"2015","journal-title":"Iran J Kidney Dis"}],"container-title":["Journal of Investigative Medicine High Impact Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2324709620946890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2324709620946890","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2324709620946890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:00:42Z","timestamp":1777449642000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2324709620946890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":10,"alternative-id":["10.1177\/2324709620946890"],"URL":"https:\/\/doi.org\/10.1177\/2324709620946890","relation":{},"ISSN":["2324-7096","2324-7096"],"issn-type":[{"value":"2324-7096","type":"print"},{"value":"2324-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2324709620946890"}}